3.41 - Skin Barrier, Microbiome and Psoriasis

dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorHIRAYAMA, A. L. S. da
dc.contributor.authorFONSECA, D. C.
dc.contributor.authorROMITI, R.
dc.date.accessioned2023-12-04T19:42:28Z
dc.date.available2023-12-04T19:42:28Z
dc.date.issued2022
dc.description.abstractPsoriasis is an inflammatory skin disorder of multifactorial etiology related to dysregulation of innate and adaptive immune responses, genetic inheritance and environmental factors. Skin and gut share features and functions. Each one has a singular ecosystem that interacts with epithelial and immune responses. The association of psoriasis with inflammatory bowel disease is well-documented, as well as immune and correlated inflammatory pathways. Recent studies have shown differences in the microbiome of psoriasis suggesting that the influence of gut and skin microbiome can possibly be related with the pathophysiology, disease's course and even its prognosis and treatment response. © 2022 Elsevier Inc. All rights reserved.
dc.identifier.citationda Hirayama, A. L. S.; Fonseca, D. C.; Romiti, R.. 3.41 - Skin Barrier, Microbiome and Psoriasis. In: . Comprehensive Gut Microbiota, v.3: ELSEVIER, 2022. p.476-481.
dc.identifier.doi10.1016/B978-0-12-819265-8.00033-4
dc.identifier.isbn978-012819265-8; 978-012822036-8
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/57266
dc.language.isoeng
dc.publisherELSEVIER
dc.relation.ispartofComprehensive Gut Microbiota
dc.rightsrestrictedAccess
dc.rights.holderCopyright ELSEVIER
dc.subjectBiologics
dc.subjectBiomarkers
dc.subjectDysbiosis
dc.subjectGastrointestinal microbiome
dc.subjectImmunomodulation
dc.subjectInterleukin-17
dc.subjectInterleukin-23
dc.subjectMicrobiota
dc.subjectProbiotics
dc.subjectPsoriasis
dc.subjectUp-regulation
dc.title3.41 - Skin Barrier, Microbiome and Psoriasis
dc.typebookPart
dc.type.categorybook chapter
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcANDRE LUIS DA SILVA HIRAYAMA
hcfmusp.contributor.author-fmusphcDANIELLE CRISTINA FONSECA CANDIAN
hcfmusp.contributor.author-fmusphcRICARDO ROMITI
hcfmusp.description.beginpage476
hcfmusp.description.endpage481
hcfmusp.description.volume3
hcfmusp.origemScopus
hcfmusp.origem.scopus2-s2.0-85151678092
hcfmusp.relation.referenceAlekseyenko A.V., Perez-Perez G.I., de Souza A., Et al., Community differentiation of the cutaneous microbiota in psoriasis, Microbiome, 1, 1, (2013)
hcfmusp.relation.referenceAssarsson M., Duvetorp A., Dienus O., Soderman J., Seifert O., Significant changes in the skin microbiome in patients with chronic plaque psoriasis after treatment with narrowband ultraviolet B, Acta Derm. Venereol., 98, pp. 428-436, (2018)
hcfmusp.relation.referenceChen Y.H., Wu C.S., Chao Y.H., Et al., Lactobacillus pentosus GMNL-77 inhibits skin lesions in imiquimod-induced psoriasis-like mice, J. Food Drug Anal., 25, pp. 559-566, (2017)
hcfmusp.relation.referenceChen Y.-J., Ho H.J., Tseng C.-H., Et al., Intestinal microbiota profiling and predicted metabolic dysregulation in psoriasis patients, Exp. Dermatol., 27, 12, (2018)
hcfmusp.relation.referenceCodoner F.M., Ramirez-Bosca A., Climent E., Et al., Gut microbial composition in patients with psoriasis, Sci. Rep., 8, 1, (2018)
hcfmusp.relation.referenceCollado M.C., Derrien M., Isolauri E., Et al., Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly, Appl. Environ. Microbiol., 73, 23, pp. 7767-7770, (2007)
hcfmusp.relation.referenceDrago L., De Grandi R., Altomare G., Et al., Skin microbiota of first cousins affected by psoriasis and atopic dermatitis, Clin. Mol. Allergy, 14, (2015)
hcfmusp.relation.referenceElfatoiki F.Z., El Azhari M., El Kettani A., Et al., Psoriasis and Staphylococcus aureus skin colonization in Moroccan patients, Pan. Afr. Med. J., 23, (2016)
hcfmusp.relation.referenceEppinga H., Konstantinov S.R., Peppelenbosch M.P., Thio H.B., The microbiome and psoriatic arthritis, Curr. Rheumatol. Rep., 16, (2014)
hcfmusp.relation.referenceFahlen A., Engstrand L., Baker B.S., Powles A., Fry L., Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin, Arch. Dermatol. Res., 304, pp. 15-22, (2012)
hcfmusp.relation.referenceFry L., Baker B.S., Triggering psoriasis: the role of infections and medications, Clin. Dermatol., 25, pp. 606-615, (2007)
hcfmusp.relation.referenceFyhrquist N., Muirhead G., Prast-Nielsen S., Et al., Microbe-host interplay in atopic dermatitis and psoriasis, Nat. Commun., 10, 1, (2019)
hcfmusp.relation.referenceGao Z., Tseng C.-H., Strober B.E., Pei Z., Blaser M.J., Substantial alterations of the cutaneous bacterial biota in psoriatic lesions, PLoS One, 3, (2008)
hcfmusp.relation.referenceGloster H.M., Gebauer L.E., Mistur R.L., Cutaneous manifestations of gastrointestinal disease, Absolute Dermatology Review, (2016)
hcfmusp.relation.referenceGrice E.A., Kong H.H., Conlan S., Et al., Topographical and temporal diversity of the human skin microbiome, Science, 324, 5931, pp. 1190-1192, (2009)
hcfmusp.relation.referenceGroeger D., O'Mahony L., Murphy E.F., Et al., Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut, Gut Microb., 4, pp. 325-339, (2013)
hcfmusp.relation.referenceGueniche A., Philippe D., Bastien P., Et al., Randomized double-blind placebo-controlled study of the effect of Lactobacillus paracasei NCC 2461 on skin reactivity, Benef. Microbes, 5, pp. 137-145, (2014)
hcfmusp.relation.referenceHidalgo-Cantabrana C., Gomez J., Delgado S., Et al., Gut microbiota dysbiosis in a cohort of patients with psoriasis, Br. J. Dermatol., 181, pp. 1287-1295, (2019)
hcfmusp.relation.referenceHsu D.K., Fung M.A., Chen H.-L., Role of skin and gut microbiota in the pathogenesis of psoriasis, an inflammatory skin disease, Med. Microecol., (2020)
hcfmusp.relation.referenceJandhyala S.M., Role of the normal gut microbiota, World J. Gastroenterol., 21, 29, (2015)
hcfmusp.relation.referenceKorman N.J., Management of psoriasis as a systemic disease: what is the evidence?, Br. J. Dermatol., 182, 4, pp. 840-848, (2019)
hcfmusp.relation.referenceLangan E.A., Kunstner A., Miodovnik M., Et al., Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis, Br. J. Dermatol., 181, pp. 1254-1264, (2019)
hcfmusp.relation.referenceLangley R.G., Krueger G.G., Griffiths C.E., Psoriasis: epidemiology, clinical features, and quality of life, Ann. Rheum. Dis., 64, (2005)
hcfmusp.relation.referenceLewis D.J., Chan W.H., Hinojosa T., Hsu S., Feldman S.R., Mechanisms of microbial pathogenesis and the role of the skin microbiome in psoriasis: a review, Clin. Dermatol., 37, 2, pp. 160-166, (2019)
hcfmusp.relation.referenceLoesche M.A., Farahi K., Capone K., Et al., Longitudinal study of the psoriasis-associated skin microbiome during therapy with ustekinumab in a randomized phase 3b clinical trial, J. Invest. Dermatol., 138, 9, pp. 1973-1981, (2018)
hcfmusp.relation.referenceMasallat D., Moemen D., State A., Gut bacterial microbiota in psoriasis: a case control study, Afr. J. Microbiol. Res., 7, 10, pp. 1337-1343, (2016)
hcfmusp.relation.referenceMichaelsson G., Gerden B., Ottosson M., Et al., Patients with psoriasis often have increased serum levels of IgA antibodies to gliadin, Br. J. Dermatol., 129, 6, pp. 667-673, (1993)
hcfmusp.relation.referenceMichaelsson G., Ahs S., Hammarstrom I., Et al., Gluten-free diet in psoriasis patients with antibodies to gliadin results in decreased expression of tissue transglutaminase and Fewer Ki67+ cells in the dermis, Acta Derm. Venereol., 83, 6, pp. 425-429, (2003)
hcfmusp.relation.referenceMyers B., Brownstone N., Reddy V., Et al., The gut microbiome in psoriasis and psoriatic arthritis, Best Pract. Res. Clin. Rheumatol., (2020)
hcfmusp.relation.referenceNatividad J.M.M., Verdu E.F., Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications, Pharmacol. Res., 69, 1, pp. 42-51, (2013)
hcfmusp.relation.referenceNorreslet L.B., Agner T., Clausen M.L., The skin microbiome in inflammatory skin diseases, Curr. Dermatol. Rep., 9, pp. 141-151, (2020)
hcfmusp.relation.referenceQuan C., Chen X.-Y., Li X., Et al., Psoriatic lesions are characterized by higher bacterial load and imbalance between Cutibacterium and Corynebacterium , J. Am. Acad. Dermatol., 82, 4, pp. 955-961, (2019)
hcfmusp.relation.referenceRinninella E., Raoul P., Cintoni M., Et al., What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases, Microorganisms, 7, 1, (2019)
hcfmusp.relation.referenceSalem I., Ramser A., Isham N., Ghannoum M.A., The gut microbiome as a major regulator of the gut-skin axis, Front. Microbiol., 9, (2018)
hcfmusp.relation.referenceSano S., Psoriasis as a barrier disease, Dermatol. Sin., 33, 2, pp. 64-69, (2015)
hcfmusp.relation.referenceScher J.U., Littman D.R., Abramson S.B., Microbiome in inflammatory arthritis and human rheumatic diseases, Arthritis Rheumatol., 68, pp. 35-45, (2016)
hcfmusp.relation.referenceShah K.R., Boland C.R., Patel M., Thrash B., Menter A., Cutaneous manifestations of gastrointestinal disease: part I, J. Am. Acad. Dermatol., 68, pp. 189.e1-189.e21, (2013)
hcfmusp.relation.referenceShapiro J., Cohen N.A., Shalev V., Et al., Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls, J. Dermatol., 46, pp. 595-603, (2019)
hcfmusp.relation.referenceSikora M., Chrabaszcz M., Maciejewski C., Et al., Intestinal barrier integrity in patients with plaque psoriasis, J. Dermatol., 45, pp. 1468-1470, (2018)
hcfmusp.relation.referenceStatnikov A., Alekseyenko A.V., Li Z., Et al., Microbiomic signatures of psoriasis: feasibility and methodology comparison, Sci. Rep., 3, pp. 2620-2631, (2013)
hcfmusp.relation.referenceTan L., Zhao S., Zhu W., Et al., The Akkermansia muciniphila is a gut microbiota signature in psoriasis, Exp. Dermatol., 27, 2, pp. 144-149, (2018)
hcfmusp.relation.referenceThrash B., Patel M., Shah K.R., Boland C.R., Menter A., Cutaneous manifestations of gastrointestinal disease: part II, J. Am. Acad. Dermatol., 68, pp. 211.e1-211.e33, (2013)
hcfmusp.relation.referenceVan Beelen A.J., Teunissen M.B., Kapsenberg M.L., de Jong E.C., Interleukin-17 in inflammatory skin disorders, Curr. Opin. Allergy Clin. Immunol., 7, pp. 374-381, (2007)
hcfmusp.relation.referenceVijayashankar M., Raghunath N., Pustular psoriasis responding to Probiotics—a new insight, Our Dermatol., 4, pp. 326-329, (2013)
hcfmusp.relation.referenceWang W.M., Jin H.Z., Skin microbiome: an actor in the pathogenesis of psoriasis, Chin. Med. J., 131, pp. 95-98, (2018)
hcfmusp.scopus.lastupdate2024-04-12
relation.isAuthorOfPublicationc7f7b3c1-74b2-493c-acf0-28314e5fbf1b
relation.isAuthorOfPublication8c786061-823d-4753-aca7-b494291b7aec
relation.isAuthorOfPublication830df912-b6d8-4dec-96d9-77c7eb49d3ee
relation.isAuthorOfPublication.latestForDiscoveryc7f7b3c1-74b2-493c-acf0-28314e5fbf1b
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_HIRAYAMA_341_Skin_Barrier_Microbiome_and_Psoriasis_2022.PDF
Tamanho:
130.13 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)